Vaxart, Inc.
- VXRT
- OTC
- Biotechnology
- Oral Vaccine Platform
- Recombinant Protein Vaccines
- Clinical-Stage Biotech
$0.48
Today +6.85%Quote Oct 19, 2026, 07:53 PM UTC
−2.16%over the last month
Max drawdown −14.3%From 1-month high −3.0%3 months −5.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Vaxart
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions.
Where the money comes from
Q2 2026 revenue $32.0M
- Government Contract$24.3M75.8%
- Collaboration Revenue$7.7M24.1%
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Employees
65
Market value
$115.5M
Quote Oct 19
Analyst target
$2.00
+320.6% from here
Floor
$0.45
4.9% below price
Resistance
$0.48
1.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VXRTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free